Skip to main content
Official EU label nameGlossary entry 4098

BUTOXYETHYL NICOTINATE

This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.

Global evidence snapshot

The resolved identity has matching regulatory evidence in 0 of 13 indexed market datasets: 0 country records and 0 EU Annex records. Every result and evidence gap is listed below.

0 markets with evidence
Markets checked
13
Markets with evidence
0
Evidence gaps
13
Resolved identifiers
3

Resolved substance identity

CAS:13912-80-61322-29-8
EC:237-684-7
Ingredient index records:
BUTOXYETHYL NICOTINATE
Cosmetic functions: SKIN CONDITIONING

3-Pyridinecarboxylic acid, 2-butoxyethyl ester

2 matched or reported names
BUTOXYETHYL NICOTINATEnicoboxil

Regulatory evidence across markets

None of the 13 markets tracked here holds an imported rule under the name BUTOXYETHYL NICOTINATE.

That is a statement about this inventory, not about the law: no imported rule is not evidence that a substance is permitted. A rule may exist under a different name, under a CAS or EC number this glossary entry does not carry, or in a dataset not yet imported.

Chemical identity and properties

PubChem 2D chemical structure for CAS 1322-29-8
CAS 1322-29-8CAS 13912-80-6PubChem CID 14866

2-Butoxyethyl 3-pyridinecarboxylate

Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic with nonivamide's capsaicin activity. Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia. Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed. — DrugBank

IUPAC name
2-butoxyethyl pyridine-3-carboxylate
Molecular formula
C12H17NO3
Molecular weight
223.27 g/mol
Exact mass
223.12084340 Da
XLogP3
2.1
Topological polar surface area
48.4 Ų
Hydrogen-bond donors
0
Hydrogen-bond acceptors
4
Covalent units
1
Defined stereocentres
0

Also known as

Nicoboxilbeta-Butoxyethyl nicotinate2-Butoxyethyl nicotinateNicoboxiloNicoboxilumGSD5B9US0WRefChem:854090237-684-7
16 more reported names
BUTOXYETHYL NICOTINATENicoboxil [INN]3-Pyridinecarboxylic acid, 2-butoxyethyl esterNicoboxil (INN)beta-Butoxyethyl nicotinate (JAN)BETA-BUTOXYETHYL NICOTINATE [JAN]SR-01000945168Nicoboxilum [INN-Latin]UNII-GSD5B9US0WNicoboxilo [INN-Spanish]Butoxyethyl 3-pyridinecarboxylateNicotinsaeure-beta-butoxyethylesterEINECS 237-684-73-Pyridinecarboxylic acid, butoxyethyl esterNICOBOXIL [MART.]NICOBOXIL [WHO-DD]
External database identifiers

Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Take this record further

Screen in a formulaOpen standalone comparison

Official source and scope

Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.

Open official Decision